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Abstract: Pneumonia is an acute pulmonary infection associated with high mortality and an immense
financial burden on healthcare systems. Staphylococcus aureus is an opportunistic pathogen capable
of inducing S. aureus pneumonia (SAP), with some lineages also showing multidrug resistance.
Given the high level of antibiotic resistance, much research has been focused on targeting S. aureus
virulence factors, including toxins and biofilm-associated proteins, in an attempt to develop effective
SAP therapeutics. Despite several promising leads, many hurdles still remain for S. aureus vaccine
research. Here, we review the state-of-the-art SAP therapeutics, highlight their pitfalls, and discuss
alternative approaches of potential significance and future perspectives.
Keywords: Staphylococcus aureus; pneumonia; virulence; therapeutics
Key Contribution: S. aureus pneumonia is associated with high fatality and a large array of virulence
factors. This review offers an in-depth analysis of the development of non-antibiotic alternatives
against S. aureus pneumonia.
1. Introduction
Pneumonia is one of the leading causes of death in developed countries, with up to 2.56 million
recorded fatalities in 2017 [1]. Its immense impact on healthcare is even more pronounced among
young children, where it accounts for 15% of all fatalities in children below five years of age [2].
Data from the United Nations Children’s Fund (UNICEF) estimates that every 39 s, a child succumbs
to pneumonia [3]. Pneumonia is defined as an acute infection of the lung parenchyma caused by one
or several co-infecting pathogens, which can be of fungal, viral, or bacterial origin [4,5]. In this review,
we focus on bacterial pneumonia, where severe episodes are associated with high mortality rates,
reaching up to 22% among ICU patients (all common pathogens) [6].
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Based on the presumed origin of the pathogen, episodes of pneumonia are generally classified
into four types that are sometimes difficult to differentiate: (i) hospital-associated pneumonia (HAP),
constituting about 20% of all nosocomial infection [7], with an onset later than 48 h after hospital
admission; (ii) ventilator-associated pneumonia (VAP), occurring after more than 48 h following
intubation; (iii) community-associated pneumonia (CAP), with an onset before or within the first
48 h post-admission [8,9]; and (iv) health-care-associated pneumonia (HCAP), occurring in patients
coming from high-risk environments such as nursing homes and extended-care facilities, in patients
receiving long term care (e.g., dialysis), or patients who had undergone recent hospitalization prior to
the current hospital admission [10]. CAP is the most common type of pneumonia and is commonly
caused by Streptococcus pneumoniae, although other pathogens, both Gram-positive and Gram-negative,
might also be involved [11] (Table 1).
Table 1. Pathogens commonly encountered in the different types of bacterial pneumonia.
Class CAP (a) [11–13] HAP/VAP [11,14] HCAP [12,15]





























spp.: species; (a) pathogen identification fails in about 50% of cases [16]; (b) both methicillin-resistant (MRSA) and
methicillin-sensitive S. aureus (MSSA).
2. Staphylococcus aureus Pneumonia
Staphylococcus aureus is a rare CAP-causing pathogen, as was shown by a longitudinal study
involving nearly 10 million pneumonia cases requiring hospitalization, where in only 1.08% of the
cases, S. aureus pneumonia (SAP) was identified as the primary diagnosis [17]. In HAP and VAP,
S. aureus has a more prominent role as the pathology differs from CAP; the importance of S. aureus
as a pneumonia pathogen was recently demonstrated in the ASPIRE-ICU observational trial [18].
However, despite a low prevalence in CAP, SAP, in general, is linked to a high case-fatality rate,
ranging from 48% to 84% [19–21]. A recent retrospective analysis of 98 SAP patients admitted to
a Spanish hospital between the years 2000 and 2014 revealed a 30-day mortality rate of 46.9% [22].
Also, SAP was recently identified as an important part of complications and mortality in SARS-CoV-2
patients [23]. This situation is even more complicated by the multidrug-resistant character of S.
aureus. The longitudinal study of Jacobs et al. also showed that, of those above-mentioned patients
hospitalized with SAP, approximately 78% of the cases were attributed to methicillin-resistant S.
aureus (MRSA) [17]. MRSA clones harbor the staphylococcal cassette chromosome mec (SCCmec),
a mobile genetic element conferring resistance to cefoxitin and many other β-lactam antibiotics [24].
Initially, pulmonary infections with MRSA were limited to HAP and VAP, and hence arose the term
hospital-associated MRSA (HA-MRSA), such as the HA-MRSA sequence type (ST)239 lineage [25].
However, in the last two decades, there has been a surge in community-associated MRSA (CA-MRSA),
which, in turn, is associated with CAP [26]. CA-MRSA infections became increasingly prevalent due to
the global spread of highly virulent clones such as the USA300 (ST8) [27]. However, the distinction
between HAP and CAP based on the causative clone has become increasingly difficult, since several
CA-MRSA clones have been observed to cause nosocomial infections [9,28,29].
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Apart from certain representative clones, HA- and CA-MRSA strains can be distinguished by
specific molecular characteristics [28], for instance, by the type of SCCmec they carry. While HA-MRSA
typically harbor the larger SCCmec types I, II, and III, CA-MRSA carry the smaller SCCmec types IV
and V [28,30,31]. SCCmec also allows for the integration of other resistance-conferring genes into the
three adjoining regions of the element [30,31]. Examples are (i) TetA(K) and TetA(L) efflux pumps,
conveying resistance to tetracyclines whose genes have integrated in the SCCmec III cassette and (ii)
integration of aminoglycosides resistance genes aacA-aphD in SCCmec II [32,33]. Such molecular events
were largely responsible for the significant surge in multidrug-resistant S. aureus clones over the last
decades. On the other hand, while CA-MRSA strains are susceptible to more antibiotic classes, they are
more virulent due to the higher abundance of virulence factors, such as Panton-Valentine leukocidin
(PVL), and a higher expression of core virulence factors [34,35]. Given the high levels of multidrug
resistance, alternative anti-infective therapeutics have recently garnered much attention, in the hope
of combating S. aureus. This review will therefore include a comprehensive overview of S. aureus
virulence factors that have been targeted in search of an effective SAP vaccine, as well as outline some
alternative therapeutic approaches that may hold promise for S. aureus research.
SAP occurs when the bacterium gains access to the epithelial cells of the upper airway due
to damage of the mucosal lining, which can be facilitated by viral infections such as influenza and
measles [36,37] or by the insertion of an endotracheal tube for mechanical ventilation. This exposure
subsequently leads to the activation of the host’s proinflammatory innate immune response,
with immune cell activation as well as neutrophil and macrophage recruitment (reviewed in [38]).
The increased neutrophil influx into the lungs, accompanied by their secreted granular toxins,
contributes to the lung pathology during SAP, by causing inflammation and necrosis of the lung
epithelial cells [39–41]. Furthermore, the adaptive immune response further exacerbates the lung
pathology. Indeed, a study in mice lacking CD4+ T cells showed improved bacterial clearance during
SAP [39]. The complex interplay between S. aureus and the adaptive immune response is reviewed
in [42], while the immunopathogenesis during pneumonia is reviewed in [43]. Apart from the role
of the immune response, the contact between S. aureus and the upper airway epithelial cells is also
believed to cause an upregulation of the bacterial virulence factors [44]. These virulence factors serve
various functions, including cell lysis through lytic toxins, immune modulation as well as biofilm
formation since several S. aureus clones have been identified as prolific biofilm formers, adding to
the pathology [45]. Given their importance in SAP pathogenesis, which in turn is linked to a high
case-mortality rate, those virulence factors, together with their molecular detection and potential as a
therapeutic target, are the focus of this review.
S. aureus is known to express a large number of virulence factors, ranging from adhesins to
toxins to immune evasion proteins, and hence, targeting these factors has been the focus of modern
anti-S. aureus therapy [46,47]. Several virulence factors of S. aureus have been studied in the context of
pneumonia. The aim of researchers was to find a suitable antigen with the following characteristics:
(i) is relevant to S. aureus pathogenesis in pneumonia; (ii) is conserved in many S. aureus strains; (iii) can
elicit a protective immune response; and (iv) shows promising results both in vitro and in vivo in
several pneumonia models.
3. Contribution of OMICs Techniques to SAP Research
Modern OMICs technologies have provided multiple tools to extensively research SAP and its
relevant virulence factors.
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3.1. Genomics
With the introduction of the whole genome sequencing (WGS) technology in the field of clinical
microbiology, more information became available on S. aureus and its virulence factors. The first two
S. aureus genomes were sequenced in 2001 by Kuroda et al., which provided completely new insights
into the genomic background of this pathogen [48]. These and future studies revealed that the core
genome is quite conserved across the S. aureus species, with variations mostly being attributed to
mobile genetic elements such as transposons, insertion sequence elements, SCCmec, etc. Shortly after
the Kuroda et al. study [48], the sequenced genome of S. aureus MW2 revealed that it harbored the
lukF and lukS genes, encoding the highly potent PVL, on a prophage element integrated into the
genome [49]. Over the next two decades, large-scale sequencing projects shed light on HA-MRSA and
their high level of antibiotic resistance, the dynamics of CA-MRSA and the impact of horizontal gene
transfer (reviewed in [35,50,51]). S. aureus genomics has been extensively reviewed [52,53].
3.2. Proteomics
Proteomics provided a valuable tool to understand the interactions of an infected host with the
pathogen, helping to refine and further focus on virulence factors unexpressed in the early phases of
the disease. A mass spectrometry experiment typically provides quantitative data of host and pathogen
proteins and have been, until now, mostly performed in simple cell culture models using human lung cell
lines to simulate single events during SAP [54–56]. Analysis of S. aureus proteins within a background
of prevalent human proteins in in vivo samples remains, however, challenging. Nevertheless, in vivo
studies already provided interesting results. For instance, in a murine S. aureus pneumonia model,
host proteins found to be associated with infection included extracellular matrix proteins, as well as
intracellular proteins such as phagosomal proteins and hemoglobin [57]. Another preliminary study,
investigating S. aureus-influenza co-infection, reported distinct differences in host protein abundance
levels, observed by two-dimensional difference gel electrophoresis (2D-DIGE), for about 200 proteins
between co-infection or single-infection groups as well as non-infected control samples [58]. A global
analysis of in vivo proteome adaptation of S. aureus in a mouse pneumonia model showed increased
abundance of glycolysis-, amino acid biosynthesis- and fermentation-related proteins as well as
virulence factors mediating oxidative stress response [56].
3.3. Metabolomics
Not only proteins but also metabolites are affected during infection, since the host and the
pathogen need to share the intracellular resources. In a cell culture study, glucose and almost all
amino acids were found inside the host cells at the time of infection [54]. In agreement with this
observation, increased levels of proteins involved in bacterial glycolysis during the course of an
infection reflect the consumption of this intracellular carbon source. Metabolomic analyses have
been successfully employed to discover specific biomarkers that can distinguish CAP from other
lung infections. Compared to patients suffering from chronic obstructive pulmonary disease (COPD),
fewer phospholipids were found in the plasma of CAP patients [59]. More interestingly, metabolomics
allows for the differentiation of pneumonia-causing pathogens. For instance, SAP is distinguishable
from S. pneumoniae-induced pneumonia based on the host’s metabolite patterns [60]. Moreover, 25-fold
lower concentrations of seven metabolites were observed in patients suffering from influenza-induced
pneumonia compared to MRSA pneumonia [61]. In this review, we analyze potential targets, some of
which are currently under development as potential therapeutics that have resulted from recent
genomic, proteomic, and metabolomics studies (Table 2).
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4. Targeting Virulence Factors Associated with Biofilms
An important factor that further adds to S. aureus pathology is the formation of biofilms [45].
A biofilm is defined as a microbially derived, sessile community embedded into an extracellular matrix,
usually consisting of polysaccharides, proteins, nucleic acids and lipids [62–64]. It attaches to both
biological (e.g., lung, intestine, heart valve, and tooth) as well as abiological surfaces, such as indwelling
medical devices (e.g., catheters, implants). Biofilms have been implicated in various persistent human
microbial infectious diseases, ranging from dental caries and periodontitis, to endocarditis, urinary tract
infections, osteomyelitis, respiratory infections in cystic fibrosis patients, and ICU pneumonia [65].
This alternative phenotype is beneficial to bacteria since it allows them to evade multiple clearance
mechanisms, such as antimicrobials and the host immune system, leading to treatment failure and
recurrent/chronic infections [62,66]. S. aureus biofilm production and virulence are closely linked,
since the main biofilm regulator, the accessory gene regulator Agr, is also vital for the expression of
numerous virulence factors [67]. Several virulence factors are known to accumulate in in vivo S. aureus
biofilms [68–70], and are thought to contribute to the structural integrity of the extracellular matrix [71].
Therefore, many of the biofilm-related virulence factors have been the target of research on S. aureus
therapeutics (Table 2).
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Table 2. Summary of virulence factors explored as potential targets for S. aureus pneumonia therapeutics.
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Table 2. Cont.
Targeted in SAP Virulence Factor Research Stage a Approach/Strategy Main Results Advantages of Targeting b
Disadvantages of
Targeting b References
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SAP: S. aureus pneumonia; Ab: Antibody; IVIG: Intravenous immunoglobulin; Hla: Alpha-toxin; Hlb: Beta-toxin; Hlg: Gamma-toxin; PSMs: Phenol soluble modulins; FnBPA: Fibronectin
binding protein A; Spa: Staphylococcal protein A; SasX: S. aureus surface protein X; Srt: Staphylococcal sortases; PVL: Panton-Valentine leukocidin; SEVs: S. aureus extracellular vesicles;
LTA: Lipoteichoic acid; LukAB: Leukocidin AB; LukED: Leukocidin ED; Fur: Ferric uptake regulator; NK: Not known. a PC: Preclinical; C: Clinical. b SEVs and OMVs: (Dis)advantages of
therapeutic use.
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4.1. Haemolysins
4.1.1. Alpha-Toxin (Hla)
Alpha toxin, also known as alpha-hemolysin (Hla), is a well-studied cytolytic protein. It is a
member of the pore-forming beta-barrel toxin family and is encoded by the hla gene, which is one of the
few virulence genes integrated into the core genome [109–113]. Hla lyses a plethora of cells including
erythrocytes, epithelial cells, endothelial cells, T cells, monocytes, macrophages, and neutrophils. It can
also stimulate a hyperinflammatory response, and disrupt epithelial and endothelial barriers, even at
sublytic levels [110,114]. The importance of Hla as a virulence factor in SAP has been researched in
mouse, rabbit and ferret pneumonia models [72,85,86,115], with studies reporting a disruptive effect
on the air-blood barrier [116]. Moreover, isogenic hla mutants consistently demonstrated reduced
infection severity compared to their wild type strains [85,114,117].
Apart from its role as a cytolytic protein, Hla also promotes biofilm formation, and hence
plays an essential role during biofilm-associated infections, both at the attachment as well as the
cell-cell binding stage [118,119]. Despite the specific pathways still being unclear, the importance
of Hla in biofilm-related S. aureus pathogenesis was demonstrated in different models using human
skin and porcine vaginal mucosal tissue [69,73], as well as using transcriptomic approaches [120].
The generation of high titers of natural antibodies (Abs) against Hla following invasive S. aureus
infections, including pneumonia, further confirms these findings [103,121,122].
Because of its importance in S. aureus pathogenesis and SAP, Hla is often targeted as a treatment
strategy. Hence, the protective potential of several anti-Hla Abs (e.g., ASN100, LC10) against
pneumonia was tested in rabbit, murine, and ferret pneumonia models, where active as well as passive
immunization showed promising results [72,74–78]. Recently, there have been several human trials
evaluating the potential use of passive immunization with anti-Hla Abs in the protection against SAP.
These trials involved anti-Hla monoclonal Abs (mAbs), such as suvratoxumab (AstraZeneca, Cambridge,
United Kingdom) [79], AR-301 (Aridis Pharmaceuticals, San Jose, CA, United States) [80], and the
multivalent antitoxin ASN100 (Arsanis, Inc., Waltham, MA, United States) that targets five different
S. aureus pore-forming toxins (“7. Multicomponent vaccines”) [81]. Despite the fact that results from
these trials did not reach statistical significance, passive immunization did show protective potential.
For instance, AR-301 reduced the time spent on mechanical ventilation, whereas suvratoxumab
reduced hospital and ICU duration as well as the duration of antibiotic treatment, while being safe and
well-tolerated [79–81]. Apart from these mAbs, some natural compounds targeting Hla might provide
a useful alternative for the prevention and/or treatment of SAP. These include the following: (i) a
modified β-cyclodextrin compound, IB201, which was discovered based on its spatial similarity to Hla,
and hence the hypothesis that it would block Hla activity with a high affinity [123]; (ii) bioflavonoid
morin hydrate [124]; (iii) aloe-emodin, an active compound from aloe vera [125], and (iv) apigenin,
an active compound from parsley [126]. All of these aforementioned compounds demonstrated
adequate protection in murine SAP models [115,124–126].
4.1.2. Beta- and Gamma-Toxin (Hlb & Hlg)
Other well-known toxins of S. aureus are beta-toxin (Hlb), a sphingomyelinase, and gamma-toxin
(Hlg), a leukocidin present in nearly all S. aureus lineages. Leukocidins are a set ofβ-barrel pore-forming
toxins, capable of targeting erythrocytes, endothelial cells and host immune cells, thus helping S. aureus
to evade the immune system and induce an inflammatory response [127]. Both Hla and Hlb are
prevalent among nearly all S. aureus lineages and have a distinct role in S. aureus biofilm formation and
pathogenesis [69,128–130]. Research on the contribution of Hlb and Hlg to SAP cytopathology is scarce,
and their overall role in S. aureus diseases is still poorly understood [131]. One study showed that
mice infected with Hlb-deficient S. aureus exhibited less severe histopathological signs of pneumonia,
including reduced levels of neutrophilic inflammation, vascular leakage and protein exudation [82].
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Some multivalent, Hlg neutralizing Abs have been developed, and will be discussed later under
“7. Multicomponent vaccines”.
4.2. Phenol-Soluble Modulins (PSMs)
Phenol-soluble modulins (PSMs) are comprised of seven amphipathic, α-helical peptides,
namely PSMα1–α4, PSMβ1–β2, and the S. aureus delta-toxin, which are widespread among
staphylococci [132–134]. PSMs are under direct control of the Agr quorum-sensing system, and they
facilitate epithelial colonization and biofilm formation due to their surfactant properties [133]. Using a
nonspecific, receptor-independent mechanism, and at micromolar concentrations, PSMs (especially
PSMα) enable the escape of S. aureus not only from human neutrophils, but also from non-professional
phagocytic cells, such as epithelial cells [133,135]. Although PSMs do not lyse cells at submicromolar
concentrations, they can trigger an inflammatory host response in neutrophils by interacting with
the formyl peptide receptor 2 (FPR2) thereby contributing to the destructive inflammatory response
characteristic of bacterial pneumonia [83,133,134].
Several studies have reported a distinct role of PSMs in SAP. In a study using human lung epithelial
cells, three PSMs demonstrated a dose-dependent cytotoxicity and interleukin (IL)-8 production [136].
Subsequent in vivo experiments using a murine S. aureus-influenza co-infection pneumonia model
showed a significantly lower mortality rate in mice infected with a PSM-deficient mutant. Thus,
PSMs contribute to a more severe outcome of pneumonia, highlighting their importance as a target for
anti-infective therapy [136].
Hence, several approaches have been explored to target PSMs, in an attempt to counteract their
pathologic function. Indirectly targeting PSMs by blocking the Agr system with an RNAIII-inhibiting
peptide resulted in a decreased bacterial burden and a lower mortality rate in a mouse pneumonia model,
along with reduced expression levels of agr, psmα and psmβ [83]. However, the protective effect of the
RNAIII-inhibiting peptide was confined to neutrophils rather than macrophages. Indirect blocking of
the transport system, the receptor binding or expression seems to hold more promise than neutralizing
individual PSMs with mAbs because of the sequence diversity and functional redundancy of the seven
PSMs [132].
4.3. Cell Wall-Anchored Proteins
Cell wall-anchored (CWA) proteins of S. aureus play a crucial role in its pathogenesis [137].
Several of those surface proteins have been associated with colonization of and adhesion to the
respiratory epithelium in animal models of SAP [138,139].
4.3.1. Fibronectin-Binding Protein A (FnBPA)
Fibronectin-binding protein A (FnBPA) is one of two highly conserved fibronectin-binding proteins
that are expressed by S. aureus and is most frequently encountered in strains isolated from patients
suffering from bacteremia or infective endocarditis [98]. Moreover, it can promote S. aureus biofilm
formation via its A domain [140]. Due to its ability to attach to the respiratory epithelium, and its
association with biofilm formation, FnBPA has also been associated with HAP and VAP [138,139].
In a recent study by Sharma-Kuinkel et al., patients with clinically cured SAP had higher IgM
titers against FnBPA compared to patients with treatment failure, suggesting a protective role for
anti-FnBPA Abs [103]. Based on this and other data, FnBPA emerged as an interesting virulence
target in S. aureus research. Indeed, several Ab-based therapies against S. aureus biofilms have been
attempted in preclinical studies, with FnBPA as a target molecule, and have been recently reviewed by
Raafat et al. [141]. To date, there are no clinical trials involving FnBPA as a single protein vaccine [142].
However, FnBPA has been used in a novel bivalent fusion vaccine, SpA-DKKAA-FnBPA37–507 (SF),
comprised of the D domain of staphylococcal protein A (SpA) and the A domain of FnBPA [98].
Active vaccination with SF in a murine pneumonia model reduced the bacterial burden in the lungs of
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infected animals, while passive immunization with rabbit polyclonal anti-SF IgG protected against
S. aureus in a mouse bacteremia model.
4.3.2. Staphylococcal Protein A (SpA)
SpA, a multifunctional CWA protein, promotes immune evasion by disturbing the
opsonophagocytic clearance of a pathogen [143]. Furthermore, it is the only B cell superantigen
produced by S. aureus [47]. The role of SpA in the pathogenesis of SAP has been attributed to
its ability to bind tumor necrosis factor receptor 1 (TNFR1) on lung epithelial cells, leading to the
activation of intracellular signaling, the expression of chemokines (such as IL-8), and the recruitment
of neutrophils [144]. This increases inflammation of the airway epithelium, and thus, contributes to
tissue damage [137].
SpA has long been regarded as a promising vaccine target for S. aureus. A non-toxigenic SpA
variant, termed SpAKKAA, was developed, where each of the five Ig-binding domains of SpA was
mutated to abolish its binding to the Fc portion of IgG and the VH3+ Fab fragments [145]. An anti-
SpAKKAA mAb, 3F6, was identified from mice immunized with SpAKKAA, and found to neutralize
the Fcy and VH3+ Fab binding activity of SpA [146]. Passive immunization of neonatal mice with
3F6 protected them against S. aureus sepsis, increased their protective immunity against subsequent
staphylococcal infections [99], and prevented nasopharyngeal colonization [100]. A human anti-SpA
mAb, 514G3, derived from an individual with naturally occurring anti-SpA Abs, effectively opsonized
S. aureus and successfully saved mice from S. aureus-mediated bacteremia [101]. 514G3 entered a phase
I-II clinical study in patients with S. aureus bacteremia and exhibited a favorable safety profile [98,102].
Further research into 514G3 in other S. aureus infection models was implied, but no concrete results
have been published so far [101].
4.3.3. S. aureus Surface Protein X (SasX)
S. aureus surface protein X (SasX) is another CWA surface protein encoded predominantly in
isolates found in Asia and Eastern Europe [84,137,147]. Its main function involves nasal colonization,
but a role in biofilm formation and evasion of neutrophil killing has been reported [84,147–150].
The interest in SasX as a target was driven by the increased risk of colonized individuals to develop
S. aureus infections [150], together with the higher incidence of sasX in HA-MRSA strains [148].
Vaccination with recombinant SasX led to an IgG1-dominated Ab response, as well as reduced acute
lung injury and inflammation in a murine lung infection model. Interestingly, both active and passive
immunizations reduced murine nasal S. aureus colonization [84].
4.3.4. Staphylococcal Sortases (Srt)
Sortases (Srt) represent a family of membrane-associated bacterial enzymes that belong to a family
of transpeptidases that is responsible for anchoring secreted proteins into the peptidoglycan layer of
Gram-positive bacteria [151]. Within S. aureus, there are two Srts, SrtA and SrtB. SrtA, the more studied
one, anchors several S. aureus polypeptides, including Spa, FnBPA and FnBPB, ClfA and ClfB [117,152]
to the cell wall via their recognition (LPXTG) motif [153]. SrtB, on the other hand, anchors the
iron-regulated surface determinant protein C (IsdC) to the S. aureus surface via its recognition sequence
NPQTN [152,153].
In SAP, only SrtB has been studied so far although with contradictory results. Bubeck et al.
reported that in a mouse lung infection model, an S. aureus Newman srtB deletion mutation only
resulted in a small reduction in mortality [85]. On the other hand, in an in vitro study by Wang et al.,
the SrtB inhibitor baicalin, which by itself does not kill S. aureus, reduced the adhesion of S. aureus to
human lung epithelial cells A549, thus reducing the S. aureus-induced damage to these cells, as well
as reducing macrophage J774 inflammatory activity [154]. Blocking the attachment of a pathogen to
the host tissue may provide a potential alternative adjunctive therapy to conventional antibiotics in
infection control [155]. Since many substrates of SrtA and SrtB are known virulence factors involved in
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the cell adhesion of S. aureus, pharmaceutical inhibitors of Srts are considered promising candidates in
anti-infective therapy [154,156,157]. However, the use of neutralizing mAbs against Srts has not been
investigated so far.
5. Other Explored S. aureus Pneumonia-Related Targets
5.1. Panton-Valentine Leukocidin (PVL)
Panton-Valentine leukocidin (PVL) is one of the best-described bi-component S. aureus toxins,
since strains harboring the lukSF-PV gene have been linked to more severe and lethal infections [131].
Unlike the other leukocidin-encoding genes, lukSF-PV is not highly prevalent in the S. aureus population
(5% prevalence) [158], but is largely associated with CAP-causing MRSA strains [159]. Upon infection,
it causes the release of a so-called “cytokine storm” (an over-activation of the immune system leading
to high inflammatory cytokine titers) in lung epithelial cells, leading to increased lung inflammation
and damage due to necrosis [41,160]. In contrast to other leukocidins, PVL does not possess hemolytic
activity, due to an alternative tertiary conformation, which is unable to recognize the Duffy antigen
receptor [161]. Nevertheless, isolates harboring the PVL-encoding genes, lukS-PV and lukF-PV,
have been linked to severe and fatal cases of necrotizing pneumonia (NP), making it an important
target for drugs developed against SAP [162–166]. The role of PVL in the pathogenesis of NP and
staphylococcal disease has been extensively reviewed in [167,168].
NP caused by PVL-harboring S. aureus can be treated with antibiotics (single or combination
treatment), as proven by in vivo studies and several clinical case reports [169–171]. However, because
of the high rates of antimicrobial resistance observed in various S. aureus lineages, other treatment
options have been explored. For instance, treatment of polymorphonuclear leukocytes (PMNs) with
commercial intravenous immunoglobulin (IVIG), often used in the treatment of severe S. aureus
infections, was able to neutralize the cytotoxic effects of PVL. Further in vivo experiments using a
rabbit SAP model showed a protective effect, both with IVIG alone and in combination with either
vancomycin or linezolid [87]. IVIG treatment resulted in up to 100% reduction in mortality when treating
CA-MRSA-induced pneumonia, whereas only 50% mortality reduction was observed when a HA-MRSA
(USA100/NRS382) strain was used [87]. Attenuated PVL components (LukS-PVT28F/K97A/S209A and
LukF-PVK102A) provided protection in a mouse sepsis model, and lead to partial protection in a
NP rabbit model [86,88]. A combination therapy based on these components is described under
“7. Multicomponent vaccines”. Other mAbs targeting LukS-PV were developed for diagnostic purposes
but were not tested for neutralizing capabilities [89]. Finally, since PVL induces a cytokine storm during
pneumonia, anti-inflammatory drugs have also been under investigation to reduce its pathologic effects.
Treatment with Anakinra (Swedish Orphan Biovitrum AB, Stockholm, Sweden), human IL-1 receptor
antagonist protein used in rheumatoid arthritis [172], resulted in decreased cytokine production in a
PVL-induced NP rabbit model. Unfortunately, Anakinra therapy did not show a comparable effect
when probed in SAP [173].
5.2. S. aureus Extracellular Vesicles (SEVs)
S. aureus extracellular vesicles (SEVs) are lipid bi-layered nanoparticles (20–200 nm in size)
containing cytosolic proteins, membrane proteins, peptidoglycan, lipoteichoic acid and many
pathogenic molecules, such as enterotoxin (SEQ), IgG-binding protein (Sbi) and hemolysins [90,91,174].
Although the mechanism remains unclear, SEV-associated proteins can influence bacteria–host
interactions during systemic infections, and induce a host immune response, albeit in a different way
than secreted proteins. Vaccination with SEVs induced an adaptive immune response, as judged by
serum SEV-reactive IgG and IgM levels and T cell responses [90–93]. Moreover, administration of
SEVs increased the resistance of S. aureus to killing by whole blood or purified human neutrophils ex
vivo and increased in vivo survival [90]. The effects of SEV immunization on SAP and mortality were
studied, where immunized mice were protected against S. aureus-induced infection [92].
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The structure of SEVs could provide a powerful and innovative strategy as drug delivery
vehicle as well as vaccination agent with many advantages, including their nano-scale size,
favorable toxicity profile, intracellular location, activation of both innate and adaptive immune
systems and non-requirement of adjuvants [91–93].
5.3. Lipoteichoic Acid (LTA)
Lipoteichoic acid (LTA) is a major CWA of most Gram-positive bacteria. Structurally, it is a polymer
of teichoic acids (TAs), which in turn consist of polyanionic repeating units bound together with
phosphodiester bonds, that is linked to the outer leaflet of the cytoplasmic membrane via a glycolipid
anchor [175]. LTA is an example of pathogen-associated molecular patterns [PAMPs], which are highly
conserved motifs recognized by pattern-recognition receptors displayed by phagocytic cells involved
in host defense, the Toll-like receptors (TLRs). Their recognition leads to the activation of intracellular
signaling cascades, ultimately resulting in a proinflammatory response and activation of the innate
immune system [176,177].
Recognition of PAMPs by TLRs is considered to be important for an appropriate immune response
against pathogens that enter the lower airways. In vitro, LTA has potent proinflammatory and
pro-apoptotic effects on human alveolar macrophages, which are the major effector cells in host defense
against respiratory tract infections [94]. Moreover, LTA, acting via TLR2, elicits neutrophil recruitment
into the pulmonary compartment both in mice as well as humans, ultimately resulting in pulmonary
inflammation [95,96]. It also activates bronchoalveolar coagulation with concurrent inhibition of
anticoagulant and fibrinolytic mechanisms, and thus affects hemostasis in humans [97].
Despite the fact that LTA is a crucial component of S. aureus, by itself, it is deemed unsuitable
as a vaccine candidate, since it is a thymus-independent antigen, which has weak immunogenicity,
and which cannot sufficiently induce immune memory. This limitation might be overcome by
alternatives, such as the conjugation of LTA as a polysaccharide antigen to a carrier protein, an approach
that has been successfully implemented in a number of carbohydrate conjugate vaccines, such as the
pneumococcal 13-valent (Prevenar 13®, Pfizer, New York City, NY, United States) and the Haemophilus
influenza typa b (HiB) conjugate vaccines [178]. Another alternative was reported by Yi et al., where they
identified a tetra-branched multiple antigenic peptide, named MAP2-3, that can mimic the epitope
of LTA [179]. Immunization with MAP2-3 as a surrogate of LTA elicited humoral immune response
(including high levels of functional LTA-specific IgG Abs), and protected mice from S. aureus systemic
infection. Moreover, passive immunization with polyclonal anti-MAP2-3 sera mitigated acute lung
injury in mice with pneumonia, and also proved useful in bacteremia and skin infection models [179].
6. Potential Unexplored Targets in S. aureus Pneumonia
6.1. Leukocidin AB (LukAB)
Leukocidin AB (LukAB; sometimes referred to as LukGH) was recently discovered, when isogenic
mutants of S. aureus Newman, with disrupted AT-, Hlg- or leukocidin ED (LukED)-encoding genes,
showed high cytotoxicity against human immune cells. Exoproteome analysis revealed LukAB as the
main contributor to human phagocyte killing [180]. Besides the active killing of innate immune cells,
LukAB also disrupts the adaptive immune response by directly killing dendritic cells, and by blocking
dendritic cell-mediated activation and proliferation of CD4+ T cells [181]. Remarkably, it was found
that LukAB not only enhances the formation of neutrophil extracellular traps (NETs), that immobilize
pathogens and attract phagocytes, but also leads to nonspecific host tissue damage [182].
Despite the cytopathogenesis of LukAB, and the fact that several neutralizing mAbs have been
developed, it has not yet been investigated in SAP models. Three LukAB-specific human mAbs,
which were generated from human B cells, neutralized LukAB cytotoxicity, and improved bacterial
clearance in a murine S. aureus sepsis model [105]. Moreover, neutralizing Abs were recently generated
from two S. aureus strains with mutated lukAB genes (LukAD39A and LukBR23E), which were able to
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block the CD11b cellular target, and prevent LukAB-dependent cell lysis in a human monocytic cell
line [106]. These components were also tested as part of a multivalent toxoid vaccine, described under
“7. Multicomponent vaccines”. Similar to what has been observed for PVL, commercial IVIG has been
shown to contain neutralizing anti-LukAB [107].
6.2. Leukocidin ED (LukED)
Leukocidin ED (LukED) is another bi-component toxin, where the tertiary protein configuration
of the core domains shows high structural similarity to those of other leukocidins [183]. The genes
encoding the toxin subunits, lukED, are highly conserved in MRSA clones isolated across the world,
with up to 85% carriage rates [131], especially among epidemic strains [184]. In addition to innate
immune cells, LukED also kills cells that carry the CCR5 receptor found on myeloid and effector memory
T lymphocytes; hence, CCR5-deficient mice are protected from LukED-mediated killing [108,185].
Therefore, analogous to LukAB, LukED is capable of disrupting the host’s innate as well as adaptive
immune systems.
Given that LukED uses CCR5 as receptor, a potentially interesting treatment option was found
in maraviroc (Pfizer, New York City, NY, United States), a small-molecule entry inhibitor of CCR5,
used in the treatment of human immunodeficiency virus (HIV) infection. HIV and LukED share the
CCR5 receptor as a cellular target, but bind to different sequence determinants [108,186]. Nevertheless,
maraviroc was shown to render murine macrophages partially resistant to LukED-mediated killing [186],
as well as to inhibit LukED functionality in human HEK293T and SupT1 cell lines [108].
6.3. Ferric Uptake Regulator (Fur)
Members of the ferric uptake regulator (Fur) family of transcription regulators are found in
most Gram-positive and Gram-negative bacteria, and are involved in the regulation of iron and
zinc metabolism [187]. Fur-mediated regulation of iron metabolism has been described in detail
in a series of recent reviews [187,188]. While investigating the role of Fur in a murine SAP model,
Torres et al. demonstrated that S. aureus lacking Fur was more susceptible to neutrophil-mediated killing.
Furthermore, the bacterial load in animals infected with the wild type S. aureus was approximately
1.5-log greater than in those animals infected with the fur deletion mutant [104]. To our knowledge,
Fur has not been investigated as a target for active or passive immunization, but since it is involved in
the expression of many pneumonia-associated S. aureus virulence factors, such as Hla, HlgA, LukED,
and LukSF, it might be a promising candidate for future vaccine studies.
7. Multicomponent Vaccines
The focus in the last couple of years has been increasingly shifting towards targeting multiple S.
aureus virulence factors simultaneously. An increasing number of studies are providing evidence that
vaccines consisting of two or more components have a higher protective potential in mouse models
than those involving either of the individual proteins [98,189]. For instance, active immunization with
the SF fusion vaccine (see “Section 4.3.1. Fibronectin-binding protein A (FnBPA)”) induced a strong Ab
response, together with a Th1/Th17-polarized cellular response, and was thus more protective against
different S. aureus strains in three different mouse models of infection (sepsis, skin infection and SAP),
compared to either of the single components, highlighting the greater potential of multicomponent
vaccine approaches [98]. Therefore, despite a seemingly long list of potential vaccine targets currently
under consideration for both preclinical and clinical trials, most researchers support the notion that
multicomponent vaccines might be the future of vaccine research [190–192].
An overview of the current S. aureus multicomponent vaccines, and their corresponding targets,
is given in Figure 1. We will highlight some in the following paragraphs.
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Figure 1. Therapeutics targeting multiple S. aureus virulence factors. The most commonly investigated
virulence factors of S. aureus are Hla: Alpha-toxin; Hlg: Gamma-toxin; LukAB: Leukocidin AB; LukED:
Leukocidin ED; PSMs: Phenol-soluble modulins and PVL: Panton Valentine leukocidin. Hla and PVL
are often incl ded in multivalent S. aureus vaccines, while PSMs are not. SAP: S. aureus pneumonia; N/A:
not available. *: also neutralizes enterotoxins A and B and toxic shock syndrome toxin 1. (1): [193,194];
(2): [195]; (3): [86]; (4): [74,196]; (5): [197,198]; (6): [199]; (7): [200]; (8): [201]. (i): [202]; (ii): [203]; (iii): [204];
(iv): [183]; (v): [205].
7.1. Therapeutics Neutralizing Multiple Leukocidins
A promising Ab tested in the context f pneumonia was Hla-F#5 (Figure 1A), whic cross-reacts
with Hla, gamma-hemolysin (HlgAB and HlgCB), LukED and PVL [193]. A study showed that passive
immunization of mice suffering from SAP with this monoclonal Ab drastically increased their survival
rate. Similar res lts were later obtained by Diep et al. in a rabbit pneumonia model [194].
More p omising results by the Diep group came from two studi s conducted in a NP rabbit
model. The first study showed that passive immunization using a combination of an Hla-specific mAb
(suvratoxumab) with a cross-neutralizing leukocidin mAb (SAN177 or SAN481) reduced mortality to
7% and 0%, respectively (Figure 1B) [195]. The second study showed similar results when attenuated
Hla (HlaH35L/H48L), combined with two attenuated PVL components (described in [88]), were used
for active immunization [86], where 100% protection from lethality was observed in immunized
rabbits (Figure 1C). Besides Hla-F#5, the Nagy research group also developed a second combination
of two mAbs, termed ASN100 (Figure 1D). ASN100 consists of ASN-1, which neutralizes Hla, PVL,
LukED, and Hlg, as well as ASN-2, which is specific to LukAB. Administration of this Ab-combination
protected human PMNs and white blood cells against lysis [196]. ASN100 was then further tested
in rabbit pneumonia models, where passive immunization increased survival and protection against
MRSA- and MSSA-induced pneumonia [74]. This led to a phase II interventional trial, where heavily S.
aureus–colonized, mechanically ventilated patients were treated with ASN-100 (Clinical Trials Identifier:
NCT02940626). However, there was no significant reduction in the incidence of SAP on day 22 (Table 3).
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Table 3. Clinical trials on S. aureus pneumonia.
Antigen(s) Year Type of Study a Study Title No. ofSubjects Aim
Clinical Trials
Identifier Countries
b Status of Trial Outcome
SpA 2015 I, R
A I-II study of the safety and
efficacy of a true human
antibody, 514G3, in subjects
sospitalized with bacteremia
due to S. aureus
52
Evaluating the safety
of 514G3 in patients
with S. aureus
bacteremia
NCT02357966 US completed Results c
PVL 2016 O, NR
Panton-Valentine leucocidin:








NCT02798497 FR completed No publishedresults
PVL 2017 O, Re
Epidemiology of
post-influenza bacterial










due to a PVL+
S. aureus
NCT03367624 FR unknown No publishedresults
Hla 2019 I, R
A phase II randomized,
double-blind,
placebo-controlled, single-dose,
dose-ranging study of the
efficacy and safety of
MEDI4893, a human
monoclonal antibody against S.
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Table 3. Cont.
Antigen(s) Year Type of Study a Study Title No. ofSubjects Aim
Clinical Trials
Identifier Countries






A phase II, randomized,
double-Blind,
placebo-controlled study to
determine the safety and
efficacy of a single dose of
ASN100 for the prevention of S.


















Hla 2020 I, R
A randomized, double-blind,
placebo-controlled, single











NCT01589185 BE, ES, FR,US completed
Preliminary
results f
a I: interventional, O: observational, R: randomized, NR: non-randomized, Re: retrospective. b BE: Belgium, BR: Brazil, BY: Belarus, CH: Switzerland, CZ: Czechia, DE: Germany, EE:
Estonia, ES: Spain, FR: France, GE: Georgia, GR: Greece, HU: Hungary, IL: Israel, IN: India, PL: Poland, PT: Portugal, RO: Romania, RS: Serbia, RU: Russian Federation, UA: Ukraine,
US: United States, ZA: South Africa. c doi: 10.1093/ofid/ofw172.1057. d doi: 10.1128/AAC.01020-16. e https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001097-34/results. f doi:
10.1007/s00134-018-5229-2.
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A final, interesting, multivalent vaccine currently under development is IBT-VO2 (Figure 1E).
This heptavalent vaccine contains rationally designed Hla, PVL LukS, LukF, LukAB, enterotoxins A
and B and toxic shock syndrome toxin 1 toxoids [197]. Due to structural similarities, the multi-subunit
vaccine elicits an antibody response that is cross-reactive with 12–15 S. aureus toxins and protects
from S. aureus disease in multiple mouse and rabbit infection models [198]. Following the current
pre-clinical phase, IBT-VO2 will enter a phase I clinical trial and hence recently received extra financial
support to advance its development [206].
7.2. Multitarget Therapeutics Involving PSMs
In an interesting approach, Wolfmeier et al. used sphingomyelin liposomes (Figure 1F),
either with or without cholesterol, to neutralize secreted PSMs, together with other virulence factors,
both in vitro (human S. aureus blood and epithelial cell infections) and in a murine dermonecrosis
model [199]. Sphingomyelin liposomes prevented cell lysis by PSMs, especially PSMα3, in all cell
types, whereas sphingomyelin liposomes containing cholesterol specifically sequestered Hla.
Both liposome types reduced the extent of murine dermonecrosis [199]. It is noteworthy to
mention that a mixture of both liposome types has recently been tested in a phase I clinical study
against severe pneumococcal pneumonia (Clinical Trials Identifier: NCT02583373), but its usefulness in
SAP is yet to be determined. Furthermore, it seems advisable to target PSMs and Hla simultaneously,
since it was shown that PSMs regulate the production of Hla both in vitro and in vivo [207]. A mutant
strain deficient for PSMα, PSMβ, and delta-toxin produced relatively lower amounts of Hla and
exhibited reduced virulence in murine skin infection and pneumonia models [191].
8. Current Issues Hampering S. aureus Vaccine Research
Despite much research focused on targeting S. aureus virulence factors, no suitable vaccine is
yet available. mAbs neutralizing single factors have been developed successfully, but many of the
conducted in vitro studies did not reach clinical potential (Table 3). This is due to the redundancy of most
of the above-mentioned virulence factors [201], as well as their complex regulatory mechanisms [208].
Targeting the regulatory factors like Fur and Agr might indeed be taken into consideration, as has
already been shown in the case of PSMs [83].
However, one needs to keep in mind that Abs solely targeting S. aureus virulence factors might
have a lower efficacy against HA-MRSA, despite the use of multicomponent vaccines. As mentioned,
above HA-MRSA lineages harbor less chromosomal virulence factors and express them in lower
quantities than CA-MRSA. Therefore, inhibiting those factors in HA-MRSA might prove to be ineffective.
Also, there have been indications that an antibody-based therapy is more efficient in SAP patients
with low S. aureus colonization levels [209], further complicating the use of Abs to treat SAP patients.
However, prophylactic use of Abs could still be considered in said cases.
Another obstacle facing S. aureus vaccine research lies in the fact that many of the virulence-targeting
therapeutics have been initially tested in murine SAP models. This is however a huge limitation,
since some toxic virulence factors, such as Hla, leukocidins, and PVL, exhibit a high level of host
tropism. Whereas PVL actively kills human and rabbit PMNs, murine PMNs are immune to its
cytotoxicity [194]. On the other hand, LukAB shows a reduced activity towards rabbit and murine
PMNs [210], which exhibit a lower affinity variant of the CD11b target [211]. The absence of appropriate
small animal models could be overcome by the use of genetically modified (i.e., “humanized”) mice.
Indeed, mice with a human hematopoietic system showed similar vulnerability to PVL as observed in
studies performed in rabbits or human cell lines [212]. Alternatively, mouse-adapted S. aureus strains
can be used to optimize murine in vivo models [213,214]. However, this might still prove to be difficult
to transfer to human-infecting strains. Instead of adapting the model, a modification of the toxin might
achieve a similar goal. For instance, a recombinant LukAB protein showed equal cytotoxicity towards
rabbit as well as human PMNs [215].
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9. Alternative Therapeutic Strategies
9.1. Bacteriophages
The current worldwide epidemic of increasing antimicrobial resistance is accompanied by a greater
understanding of the damage broad spectrum antibiotics have on the healthy microbiome. Hence,
alternative approaches—other than antimicrobials—have lately garnered the attention of researchers,
in an attempt to treat multidrug resistant pathogens. One such alternative, which has also been explored
in the context of SAP, is phage therapy, where bacteriophages are used to selectively target the infecting
pathogen. In one study involving mice with lung-derived septicemia, treatment with S. aureus ϕS13′
increased murine survival from 10% to 67% [216]. Another randomized, blinded, controlled in vivo
experimental study compared the efficacy of phage therapy versus teicoplanin treatment in rats with
MRSA-induced VAP [217]. The administration of a four phage cocktail, increased rat survival to 58%,
comparable to teicoplanin treatment (50%). In another study, conducted by the same research group
and published in 2020, rats with MRSA-induced VAP were treated prophylactically with nebulized
bacteriophages, resulting in increased survival (70% versus 0% in the control group) as well as a
reduced bacterial burden [218].
Another promising treatment option involves the bacteriophage cocktail AB-SA01 that contains
three myoviruses related to Staphylococcus ϕK [219]. The product killed 94.5% of the 205 clinical
S. aureus isolates tested in vitro, which included both MRSA as well as vancomycin-intermediate
S. aureus (VISA) [219]. Moreover, in a BALB/c mouse acute pneumonia model, it was shown that
bacterial clearance in the lungs of AB-SA01-treated mice was comparable to that in mice treated with
vancomycin. An additional benefit of AB-SA01 over antibiotics is that the frequency of spontaneous
resistance was found to be low. In clinical testing, AB-SA01 was deemed safe and well-tolerated
when administered intranasally in patients suffering from chronic rhinosinusitis, and thus became
the first clinical trial with intravenous phage therapy to be approved in the USA [220]. In an ensuing
single-arm, non-comparative clinical trial, intravenous administration of AB-SA01 in 13 patients
with severe S. aureus infections, including endocarditis and septic shock, did not show any adverse
reactions. More interestingly, eight patients survived and showed clinical improvement after 14 days
of treatment [221]. Further controlled clinical trials are to be expected.
Besides using the phage itself for treatment, other studies explored a possible use of phage-derived
lysines. A 2015 study investigating the efficacy of LysGH15 showed that treatment with the lysine
achieved 80% survival in mice with SAP. The survival rate further increased to 100% when LysGH15
was combined with apigenin, a naturally occurring flavonoid [222]. In a second study, conducted in
2018, phage-derived endolysin SAL200 was tested in murine SAP, and achieved higher survival,
lower bacterial burden, and improved lung histopathology compared to the control group [223].
Benefits of phage therapy are the little to no adverse host reactions, generally low frequency of
spontaneous resistance against the bacteriophage, and their ability to target and kill multidrug resistant
clones [219]. However, phage therapy also has its limitations, including strain specificity and the
potential for immunogenicity preventing repeat dosing [224].
9.2. Outer Membrane Vesicles (OMVs)
Another interesting approach exploits bacterial outer membrane vesicles (OMVs) as a vehicle
for delivering foreign antigens into the host, with the aim of eliciting protective immune responses.
For instance, Irene et al. expressed five highly conserved S. aureus vaccine candidates (HlaH35L,
SpAKKAA, FhuD2, Csa1A, and LukE) in Escherichia coli as fusions to a lipoprotein leader sequence.
The lipoproteins were compartmentalized in OMVs and elicited high antigen-specific Ab titers in
immunized mice. Moreover, the penta-valent OMV-based S. aureus vaccine protected mice from
challenge with the S. aureus Newman strain in a sepsis model [225]. This suggests that those engineered
OMVs could represent a valid alternative for the development of an efficacious S. aureus vaccine.
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10. Concluding Remarks
In conclusion, much effort has been invested in exploring S. aureus virulence factors,
thus improving our understanding of their mode of action and their role in SAP pathogenesis
(Table 2). Classical immunization strategies involving the use of Abs have led to the development
of several promising therapeutics. However, many hurdles still remain in the path of an effective
SAP vaccine given the intricate genetic background of S. aureus (Table 4). Finally, apart from classical
methods of active and passive immunization, alternative approaches should be considered (Table 4).
SEVs and OMVs could provide innovative ways of drug delivery, while phage therapy provides
an interesting lead showing some success in different clinical settings. A systems biology approach
combining data generated from genomic, proteomic, and metabolomic studies is necessary to further
our knowledge on bacteria–host interactions. Moreover, much attention has recently been dedicated
to the respiratory microbiome and its effect on pneumonia pathogenesis. These studies debate
Koch’s postulates and raise the question that if one pathogen is suppressed, another might prevail.
More research will hence be required in these directions in order to develop a safe and effective
SAP therapeutic.
Table 4. Current issues hampering S. aureus vaccine research and alternative therapeutic strategies.
(A) Issues Hampering S. aureus Vaccine Research Potential Solution References
Redundancy of S. aureus virulence factors
Target regulatory factors [83,201,208]Genetic variations among S. aureus isolates/lineages
Complex regulatory mechanisms
Lower presence and expression of virulence factors in HA-MRSA [34,35]
Antibody-based therapy less effective in highly
colonized SAP patients
Prophylactic antibody use
to be explored [209]
High tropism of S. aureus virulence factors
Inferior transferability of conventional mouse models
into clinical research
Humanized mice [194,210–215]
10.3390/ijms21197061Mouse-adapted S. aureus strains
Recombinant toxins
(B) Alternative Therapeutic Strategies Explored in SAP References
Bacteriophages Yes [216–224]
Outer membrane vesicles No [225]
Nanoparticles (nasal vaccination) No 10.1016/j.addr.2008.09.005
Nanoparticles (treatment of pulmonary diseases) Yes
10.1002/wnan.1401
10.1038/s41551-017-0187-5
Antimicrobial peptides (antibiotic alternative) No 10.1093/jac/dkw381
HA-MRSA: Hospital-associated methicillin-resistant S. aureus; SAP: S. aureus pneumonia.
Author Contributions: Conceptualization, S.M.-K.; data collection and writing: J.V., D.R., K.S., L.T. and N.N.;
writing—compilation original draft, J.V.; writing—review and editing, J.V., D.R., K.S., L.T., N.N., B.S., W.J.v.W. and
S.M.-K.; supervision, S.M.-K.; All authors have read and agreed to the published version of the manuscript.
Funding: J.V.: K.S., L.T., and N.N. were supported by the Innovative Medicines Initiative project COMBACTE
(Combatting Bacterial Resistance in Europe). This research project receives support from the Innovative Medicines
Initiative Joint Undertaking under grant agreement n◦ 115523 resources of which are composed of financial
contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in
kind contribution. J.V. was also supported by IWT-SBO project #140746.
Acknowledgments: We would like to thank Barbara M. Bröker and Uwe Völker (University Medicine Greifswald)
for their valuable input in the drafting of the manuscript.
Conflicts of Interest: J.V., D.R., K.S., L.T., N.N., W.W. and S.M.-K. do not have a commercial or other association
that poses a conflict of interest. B.S. is employed by AstraZeneca, manufacturer of monoclonal antibodies.
The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the
writing of the manuscript, or in the decision to publish the results.
References
1. Dadonaite, B. Pneumonia. Available online: https://ourworldindata.org/pneumonia (accessed on
3 September 2020).
2. World Health Organization. Pneumonia. Available online: https://www.who.int/news-room/fact-sheets/
detail/pneumonia (accessed on 3 September 2020).
Toxins 2020, 12, 721 20 of 31
3. United Nations Children’s Fund. Pneumonia. Available online: https://data.unicef.org/topic/child-health/
pneumonia/ (accessed on 3 September 2020).
4. MacKenzie, G. The definition and classification of pneumonia. Pneumonia 2016, 8, 1–5. [CrossRef] [PubMed]
5. Centers for Disease Control and Prevention. Causes of Pneumonia. Available online: https://www.cdc.gov/
pneumonia/causes.html (accessed on 30 June 2020).
6. Laterre, P.-F.; Garber, G.; Levy, H.; Wunderink, R.; Kinasewitz, G.T.; Sollet, J.-P.; Maki, D.G.; Bates, B.;
Yan, S.C.B.; Dhainaut, J.-F. Severe community-acquired pneumonia as a cause of severe sepsis: Data from the
PROWESS study. Crit. Care Med. 2005, 33, 952–961. [CrossRef] [PubMed]
7. Dalhoff, K.; Abele-Horn, M.; Andreas, S.; Deja, M.; Ewig, S.; Gastmeier, P.; Gatermann, S.; Gerlach, H.;
Grabein, B.; Heußel, C.P.; et al. Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit
nosokomialer Pneumonie—Update 2017—S3 Guideline of the German Society for Anaesthesiology and
Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and
Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German
Radiological Society and the Society for Virology. Pneumologie 2018, 72, 15–63. [CrossRef] [PubMed]
8. Kalil, A.C.; Metersky, M.L.; Klompas, M.; Muscedere, J.; Sweeney, D.A.; Palmer, L.B.; Napolitano, L.M.;
O’Grady, N.P.; Bartlett, J.G.; Carratalà, J.; et al. Management of Adults with Hospital-acquired and
Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of
America and the American Thoracic Society. Clin. Infect. Dis. 2016, 63, e61–e111. [CrossRef] [PubMed]
9. Uhlemann, A.-C.; Otto, M.; Lowy, F.D.; DeLeo, F.R. Evolution of community- and healthcare-associated
methicillin-resistant Staphylococcus aureus. Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis.
2014, 21, 563–574. [CrossRef] [PubMed]
10. Kollef, M.H.; Micek, S.T. Staphylococcus aureus pneumonia: A “superbug” infection in community and
hospital settings. Chest 2005, 128, 1093–1097. [CrossRef]
11. Lanks, C.W.; Musani, A.I.; Hsia, D.W. Community-acquired Pneumonia and Hospital-acquired Pneumonia.
Med. Clin. N. Am. 2019, 103, 487–501. [CrossRef]
12. Micek, S.T.; Kollef, K.E.; Reichley, R.M.; Roubinian, N.; Kollef, M.H. Health Care-Associated Pneumonia
and Community-Acquired Pneumonia: A Single-Center Experience. Antimicrob. Agents Chemother. 2007, 51,
3568–3573. [CrossRef]
13. Ewig, S.; Höffken, G.; Kern, W.V.; Rohde, G.; Flick, H.; Krause, R.; Ott, S.R.; Bauer, T.; Dalhoff, K.;
Gatermann, S.; et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und
Prävention—Update 2016. Pneumologie 2016, 70, 151–200. [CrossRef]
14. Rotstein, C.; Evans, G.; Born, A.; Grossman, R.; Light, R.B.; Magder, S.; McTaggart, B.; Weiss, K.; Zhanel, G.G.
Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in
Adults. Can. J. Infect. Dis. Med. Microbiol. 2008, 19, 19–53. [CrossRef]
15. Qi, F.; Zhang, G.-X.; She, D.-Y.; Liang, Z.-X.; Wang, R.-T.; Yang, Z.; Chen, L.-A.; Cui, J.-C. Healthcare-associated
Pneumonia. Chin. Med. J. 2015, 128, 2707–2713. [CrossRef] [PubMed]
16. Torres, A.; Lee, N.; Cilloniz, C.; Vila, J.; Van Der Eerden, M. Laboratory diagnosis of pneumonia in the
molecular age. Eur. Respir. J. 2016, 48, 1764–1778. [CrossRef] [PubMed]
17. Jacobs, D.M.; Shaver, A. Prevalence of and outcomes from Staphylococcus aureus pneumonia among
hospitalized patients in the United States, 2009–2012. Am. J. Infect. Control. 2017, 45, 404–409. [CrossRef]
[PubMed]
18. Paling, F.P.; Hazard, D.; Bonten, M.J.M.; Goossens, H.; Jafri, H.S.; Malhotra-Kumar, S.; Sifakis, F.; Weber, S.;
Kluytmans, J.A.J.W.; for the ASPIRE-ICU Study Team. Association of Staphylococcus aureus Colonization
and Pneumonia in the Intensive Care Unit. JAMA Netw. Open 2020, 3, e2012741. [CrossRef]
19. Watanakunakorn, C. Bacteremic Staphylococcus aureus Pneumonia. Scand. J. Infect. Dis. 1987, 19, 623–627.
[CrossRef]
20. DeRyke, C.A.; Lodise, T.P.; Rybak, M.J.; McKinnon, P.S. Epidemiology, Treatment, and Outcomes of
Nosocomial Bacteremic Staphylococcus aureus Pneumonia. Chest 2005, 128, 1414–1422. [CrossRef]
21. González, C.; Rubio, M.; Romero-Vivas, J.; González, M.; Picazo, J.J. Staphylococcus aureus bacteremic
pneumonia: Differences between community and nosocomial acquisition. Int. J. Infect. Dis. IJID 2003, 7,
102–108. [CrossRef]
Toxins 2020, 12, 721 21 of 31
22. De La Calle, C.; Morata, L.; Cobos-Trigueros, N.; Martinez, J.A.; Cardozo, C.; Mensa, J.; Soriano, A.
Staphylococcus aureus bacteremic pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2016, 35, 497–502.
[CrossRef]
23. Sharov, K.S. SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020:
Secondary bacterial pneumonia and viral co-infections. J. Glob. Health 2020, 10. [CrossRef]
24. Peacock, S.J.; Paterson, G.K. Mechanisms of Methicillin Resistance in Staphylococcus aureus.
Annu. Rev. Biochem. 2015, 84, 577–601. [CrossRef]
25. Chambers, H.F.; DeLeo, F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Genet.
2009, 7, 629–641. [CrossRef] [PubMed]
26. Fitzgerald, J.R. Livestock-associated Staphylococcus aureus: Origin, evolution and public health threat.
Trends Microbiol. 2012, 20, 192–198. [CrossRef] [PubMed]
27. Nimmo, G. USA300 abroad: Global spread of a virulent strain of community-associated methicillin-resistant
Staphylococcus aureus. Clin. Microbiol. Infect. 2012, 18, 725–734. [CrossRef]
28. Peng, H.; Liu, D.; Ma, Y.; Gao, W. Comparison of community- and healthcare-associated methicillin-resistant
Staphylococcus aureus isolates at a Chinese tertiary hospital, 2012–2017. Sci. Rep. 2018, 8, 17916. [CrossRef]
[PubMed]
29. Drougka, E.; Foka, A.; Liakopoulos, A.; Doudoulakakis, A.; Jelastopulu, E.; Chini, V.; Spiliopoulou, A.;
Levidiotou, S.; Panagea, T.; Vogiatzi, A.; et al. A 12-year survey of methicillin-resistant Staphylococcus
aureus infections in Greece: ST80-IV epidemic? Clin. Microbiol. Infect. 2014, 20, O796–O803. [CrossRef]
30. Lee, A.S.; De Lencastre, H.; Garau, J.; Kluytmans, J.; Malhotra-Kumar, S.; Peschel, A.; Harbarth, S.
Methicillin-resistant Staphylococcus aureus. Nat. Rev. Dis. Prim. 2018, 4, 18033. [CrossRef]
31. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements
(IWG-SCC). Classification of Staphylococcal Cassette Chromosome mec (SCCmec): Guidelines for Reporting
Novel SCCmec Elements. Antimicrob. Agents Chemother. 2009, 53, 4961–4967. [CrossRef]
32. Foster, T.J. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.
FEMS Microbiol. Rev. 2017, 41, 430–449. [CrossRef]
33. Jensen, S.O.; Lyon, B.R. Genetics of antimicrobial resistance in Staphylococcus aureus. Futur. Microbiol. 2009,
4, 565–582. [CrossRef]
34. Wang, X.; Li, X.; Liu, W.; Huang, W.; Fu, Q.; Li, M. Molecular Characteristic and Virulence Gene Profiles
of Community-Associated Methicillin-Resistant Staphylococcus aureus Isolates from Pediatric Patients in
Shanghai, China. Front. Microbiol. 2016, 7, 1818. [CrossRef]
35. Otto, M. Community-associated MRSA: What makes them special? Int. J. Med. Microbiol. 2013, 303, 324–330.
[CrossRef] [PubMed]
36. Liu, G.Y. Molecular Pathogenesis of Staphylococcus aureus Infection. Pediatr. Res. 2009, 65, 71R–77R.
[CrossRef]
37. Médecins Sans Frontières. Staphylococcal Pneumonia. In Clinical Guidelines—Diagnosis and Treatment Manual;
Medecins Sans Frontieres: Geneva, Switzerland, 2020.
38. Fournier, B.; Philpott, D.J. Recognition of Staphylococcus aureus by the Innate Immune System.
Clin. Microbiol. Rev. 2005, 18, 521–540. [CrossRef] [PubMed]
39. Parker, D.; Ryan, C.L.; Alonzo, F.; Torres, V.J.; Planet, P.J.; Prince, A.S. CD4+ T cells promote the pathogenesis
of Staphylococcus aureus pneumonia. J. Infect. Dis. 2014, 211, 835–845. [CrossRef] [PubMed]
40. Spaan, A.N.; Surewaard, B.G.; Nijland, R.; Van Strijp, J.A.G. Neutrophils Versus Staphylococcus aureus:
A Biological Tug of War. Annu. Rev. Microbiol. 2013, 67, 629–650. [CrossRef] [PubMed]
41. Shambat, S.M.; Chen, P.; Hoang, A.T.N.; Bergsten, H.; Vandenesch, F.; Siemens, N.; Lina, G.; Monk, I.R.;
Foster, T.J.; Arakere, G.; et al. Modelling staphylococcal pneumonia in a human 3D lung tissue model system
delineates toxin-mediated pathology. Dis. Model. Mech. 2015, 8, 1413–1425. [CrossRef]
42. Karauzum, H.; Datta, S.K. Adaptive Immunity against Staphylococcus aureus. Curr. Top. Microbiol. Immunol.
2016, 409, 419–439. [CrossRef]
43. Parker, D.; Prince, A. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin. Immunopathol.
2012, 34, 281–297. [CrossRef]
44. Novick, R.P. Autoinduction and signal transduction in the regulation of staphylococcal virulence.
Mol. Microbiol. 2003, 48, 1429–1449. [CrossRef]
Toxins 2020, 12, 721 22 of 31
45. Vanhommerig, E.; Moons, P.; Pirici, D.; Lammens, C.; Hernalsteens, J.-P.; De Greve, H.; Kumar-Singh, S.;
Goossens, H.; Malhotra-Kumar, S. Comparison of Biofilm Formation between Major Clonal Lineages of
Methicillin Resistant Staphylococcus aureus. PLoS ONE 2014, 9, e104561. [CrossRef]
46. Kong, C.; Neoh, H.-M.; Nathan, S. Targeting Staphylococcus Aureus Toxins: A Potential form of Anti-Virulence
Therapy. Toxins 2016, 8, 72. [CrossRef] [PubMed]
47. Tam, K.; Torres, V.J. Staphylococcus aureus Secreted Toxins and Extracellular Enzymes. Microbiol. Spectr.
2019, 7, 7. [CrossRef]
48. Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Oguchi, A.; Aoki, K.-I.;
Nagai, Y.; et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 2001, 357,
1225–1240. [CrossRef]
49. Baba, T.; Takeuchi, F.; Kuroda, M.; Yuzawa, H.; Aoki, K.-I.; Oguchi, A.; Nagai, Y.; Iwama, N.; Asano, K.;
Naimi, T.; et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet
2002, 359, 1819–1827. [CrossRef]
50. Lindsay, J.A. Hospital-associated MRSA and antibiotic resistance—What have we learned from genomics?
Int. J. Med. Microbiol. 2013, 303, 318–323. [CrossRef]
51. Lindsay, J.A. Staphylococcus aureus genomics and the impact of horizontal gene transfer. Int. J. Med. Microbiol.
2014, 304, 103–109. [CrossRef]
52. Lindsay, J.A. Staphylococci: Evolving Genomes. Microbiol. Spectr. 2019, 7, 485–498. [CrossRef]
53. Fitzgerald, J.R.; Holden, M.T.G. Genomics of Natural Populations of Staphylococcus aureus.
Annu. Rev. Microbiol. 2016, 70, 459–478. [CrossRef]
54. Surmann, K.; Simon, M.; Hildebrandt, P.; Pförtner, H.; Michalik, S.; Stentzel, S.; Steil, L.; Dhople, V.M.;
Bernhardt, J.; Schlüter, R.; et al. A proteomic perspective of the interplay of Staphylococcus aureus and
human alveolar epithelial cells during infection. J. Proteom. 2015, 128, 203–217. [CrossRef]
55. Richter, E.; Harms, M.; Ventz, K.; Nölker, R.; Fraunholz, M.J.; Mostertz, J.; Hochgräfe, F. Quantitative
Proteomics Reveals the Dynamics of Protein Phosphorylation in Human Bronchial Epithelial Cells during
Internalization, Phagosomal Escape, and Intracellular Replication of Staphylococcus aureus. J. Proteome Res.
2016, 15, 4369–4386. [CrossRef]
56. Michalik, S.; Depke, M.; Murr, A.; Salazar, M.G.; Kusebauch, U.; Sun, Z.; Meyer, T.C.; Surmann, K.;
Pförtner, H.; Hildebrandt, P.; et al. A global Staphylococcus aureus proteome resource applied to the in vivo
characterization of host-pathogen interactions. Sci. Rep. 2017, 7, 9718. [CrossRef] [PubMed]
57. Ventura, C.L.; Higdon, R.; Kolker, E.; Skerrett, S.J.; Rubens, C.E. Host Airway Proteins Interact with
Staphylococcus aureus during Early Pneumonia. Infect. Immun. 2008, 76, 888–898. [CrossRef] [PubMed]
58. Prescott, M.A.; Pastey, M.K. Identification of Unique Blood and Urine Biomarkers in Influenza Virus and
Staphylococcus aureus Co-infection: A Preliminary Study. Biomark. Insights 2010, 5, 145–151. [CrossRef]
[PubMed]
59. Arshad, H.; Alfonso, J.C.L.; Franke, R.; Michaelis, K.; Araujo, L.; Habib, A.; Zboromyrska, Y.; Lücke, E.;
Strungaru, E.; Akmatov, M.K.; et al. Decreased plasma phospholipid concentrations and increased acid
sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia. J. Transl. Med. 2019,
17, 1–18. [CrossRef] [PubMed]
60. Slupsky, C.M.; Cheypesh, A.; Chao, D.V.; Fu, H.; Rankin, K.N.; Marrie, T.J.; Lacy, P. Streptococcus pneumoniae
and Staphylococcus aureus Pneumonia Induce Distinct Metabolic Responses. J. Proteome Res. 2009, 8,
3029–3036. [CrossRef] [PubMed]
61. Ambroggio, L.; Florin, T.A.; Shah, S.S.; Ruddy, R.; Yeomans, L.; Trexel, J.; Stringer, K.A. Emerging Biomarkers
of Illness Severity: Urinary Metabolites Associated with Sepsis and Necrotizing Methicillin-Resistant
Staphylococcus aureus Pneumonia. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2017, 37, 1033–1042.
[CrossRef]
62. Archer, N.K.; Mazaitis, M.J.; Costerton, J.W.; Leid, J.G.; Powers, M.E.; Shirtliff, M.E. Staphylococcus aureus
biofilms. Virulence 2011, 2, 445–459. [CrossRef]
63. Otto, M. Staphylococcal Biofilms. Microbiol. Spectr. 2018, 6. [CrossRef]
64. Otto, M. Staphylococcal Biofilms. Curr. Top. Microbiol. Immunol. 2008, 322, 207–228.
65. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial Biofilms: A Common Cause of Persistent Infections.
Science 1999, 284, 1318–1322. [CrossRef]
Toxins 2020, 12, 721 23 of 31
66. Parsek, M.R.; Singh, P.K. Bacterial Biofilms: An Emerging Link to Disease Pathogenesis. Annu. Rev. Microbiol.
2003, 57, 677–701. [CrossRef]
67. Wang, B.; Muir, T.W. Regulation of Virulence in Staphylococcus Aureus: Molecular Mechanisms and
Remaining Puzzles. Cell Chem. Biol. 2016, 23, 214–224. [CrossRef]
68. Scherr, T.D.; Hanke, M.L.; Huang, O.; James, D.B.A.; Horswill, A.R.; Bayles, K.W.; Fey, P.D.; Torres, V.J.;
Kielian, T. Staphylococcus aureus Biofilms Induce Macrophage Dysfunction Through Leukocidin AB and
Alpha-Toxin. mBio 2015, 6, e01021-15. [CrossRef] [PubMed]
69. Den Reijer, P.M.; Haisma, E.M.; Lemmens-den Toom, N.A.; Willemse, J.; Koning, R.A.; Demmers, J.A.;
Dekkers, D.H.; Rijkers, E.; El Ghalbzouri, A.; Nibbering, P.H.; et al. Detection of Alpha-Toxin and Other
Virulence Factors in Biofilms of Staphylococcus aureus on Polystyrene and a Human Epidermal Model.
PLoS ONE 2016, 11, e0145722. [CrossRef]
70. Lei, M.G.; Gupta, R.K.; Lee, C.Y. Proteomics of Staphylococcus aureus biofilm matrix in a rat model of
orthopedic implant-associated infection. PLoS ONE 2017, 12, e0187981. [CrossRef] [PubMed]
71. Graf, A.C.; Leonard, A.; Schäuble, M.; Rieckmann, L.M.; Hoyer, J.; Maass, S.; Lalk, M.; Becher, D.; Pané-Farré, J.;
Riedel, K. Virulence Factors Produced by Staphylococcus aureus Biofilms Have a Moonlighting Function
Contributing to Biofilm Integrity. Mol. Cell. Proteom. 2019, 18, 1036–1053. [CrossRef] [PubMed]
72. Diep, B.A.; Hilliard, J.J.; Le, V.T.M.; Tkaczyk, C.; Le, H.N.; Tran, V.G.; Rao, R.L.; Dip, E.C.; Pereira-Franchi, E.P.;
Cha, P.; et al. Targeting Alpha Toxin to Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of
Staphylococcus aureus Necrotizing Pneumonia. Antimicrob. Agents Chemother. 2017, 61, e02456-16.
[CrossRef]
73. Anderson, M.J.; Lin, Y.-C.; Gillman, A.N.; Parks, P.J.; Schlievert, P.M.; Peterson, M.L. Alpha-Toxin Promotes
Staphylococcus Aureus Mucosal Biofilm Formation. Front. Cell. Infect. Microbiol. 2012, 2, 64. [CrossRef]
74. Stulik, L.; Rouha, H.; Labrousse, D.; Visram, Z.C.; Badarau, A.; Maierhofer, B.; Groß, K.; Weber, S.;
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